lock Open Access lock Peer-Reviewed




Response to the “Glasgow Prognostic Score as A Marker of Mortality After TAVI”

İpek BüberI

DOI: 10.21470/1678-9741-2021-0577

Dear Editor,

I have read the article entitled “Glasgow Prognostic Score as a Marker of Mortality after TAVI”, by Abacioglu et al. and published in the BJCVS, with great interest[1]. The investigators reported that the Glasgow prognostic score (GPS) is an easy, noninvasive laboratory test which may be used as a predictive biomarker for outcomes in patients undergoing transcatheter aortic valve implantation (TAVI).

Aortic stenosis is one of the most common valve diseases in the worldwide population[2], and the increase in the elderly population increases the frequency of TAVI, which is a well-established alternative to surgical valve replacement in patients at high surgical risk[3]. Conventional scoring systems, including logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE), EuroSCORE II, and the Society of Thoracic Surgeons risk score, are used to determine the surgical risk in patients undergoing TAVI[4]. However, these traditional risk scoring systems are sometimes inadequate to predict periprocedural and long-term mortality in patients undergoing TAVI. GPS is an inflammation-based prognostic score evaluated using the elevation of C-reactive protein and decrease in albumin concentration[5]. It is usually used to assess the risk in cancer patients undergoing surgery[6], and this score predicts the outcomes for idiopathic pulmonary fibrosis[7], systemic lupus erythematosus[8], and inflammatory bowel diseases[9].

In this context, assessment of the GPS value, which is an easy and noninvasive tool, can be beneficial to determine the prognosis of patients undergoing TAVI because there is a requirement for new scores that will provide prognostic information in TAVI patients.


1. Abacioglu OO, Koyunsever NY, Kilic S, Yildirim A, Kurt IH. Glasgowprognostic score as a marker of mortality after TAVI. Braz J Cardiovasc Surg.2021;36(6):796-801. doi:10.21470/1678-9741-2020-0269. [MedLine]

2. Rajamannan NM, Bonow RO, Rahimtoola SH. Calcific aortic stenosis: anupdate. Nat Clin Pract Cardiovasc Med. 2007;4(5):254-62.doi:10.1038/ncpcardio0827.

3. Bach DS, Siao D, Girard SE, Duvernoy C, McCallister BD Jr, GualanoSK. Evaluation of patients with severe symptomatic aortic stenosis who do notundergo aortic valve replacement: the potential role of subjectivelyoverestimated operative risk. Circ Cardiovasc Qual Outcomes. 2009;2(6):533-9.doi:10.1161/CIRCOUTCOMES.109.848259.

4. Alpaslan E, Dursun H, Tanriverdi Z, Colluoglu T, Kaya D. New riskfactors in determining long-term mortality in patients undergoing TAVI: can theconventional risk scores be used as a long-term mortality predictor? KardiolPol. 2020;78(3):219-26. doi:10.33963/KP.15183. [MedLine]

5. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The Glasgow prognostic score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:52. doi:10.1186/1471-2407-13-52.

6. Eren T, Burcu B, Tombalak E, Ozdemir T, Leblebici M, Ozemir IA, et al. Clinical significance of the glasgow prognostic score for survival after colorectal cancer surgery. J Gastrointest Surg. 2016;20(6):1231-8. doi:10.1007/s11605-016-3114-2.

7. Kang HS, Cho KW, Kwon SS, Kim YH. Prognostic significance of glasgow prognostic score in patients with acute exacerbation of idiopathic pulmonary fibrosis. Respirology. 2018;23(2):206-12. doi:10.1111/ resp.13184.

8. Delcea C, Dima A, Jurcut C, Caraiola S, Badea C, Nitescu D, et al. Utility of the Glasgow Prognostic Score in systemic lupus erythematosus, in a single center cohort of 130 patients. Ann Rheum Dis. 2015;74(Suppl 2):638.2–8.

9. Zhao C, Ding C, Xie T, Zhang T, Dai X, Wei Y, et al. Validation and optimization of the systemic inflammation-based modified glasgow prognostic score in predicting postoperative outcome of inflammatory bowel disease: preliminary data. Sci Rep. 2018;8(1):747. doi:10.1038/ s41598-017-18771-3.

CCBY All scientific articles published at are licensed under a Creative Commons license


All rights reserved 2017 / © 2024 Brazilian Society of Cardiovascular Surgery DEVELOPMENT BY